Pennington Biomedical Research Center
Baton Rouge, Louisiana, 70808, United States
Location status: Recruiting
Location contact
Jessica St. Romain, MA
CONTACT
Melissa Harris, MA
CONTACT
Owen Carmichael, PhD
CONTACT
Robert L Newton, Jr., PhD
CONTACT
NCT Number: NCT03890861
The RAATE proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. There are three main objectives of the protocol: 1) to determine if a physical activity intervention tailored to older African American adults is effective in modifying cognitive function associated with Alzheimer's Disease, 2) to determine if a physical activity intervention tailored to older African American adults is effective in modifying brain function and structure associated with Alzheimer's Disease, and 3) to determine if a physical activity promotion intervention tailored to African American adults is effective at enhancing physiological parameters. The primary endpoints for the study are episodic memory and executive functioning. The secondary outcomes include anthropometry, blood pressure, brain activation, cerebral blood flow, volume of whole brain and white matter hyperintensities, cardiorespiratory fitness, objectively measured physical activity, circulating hormones, and telomere length.
Interested in participating?
Request Info60 year and older
All sexes
Interventional
Not applicable
Baton Rouge, Louisiana, 70808, United States
Location status: Recruiting
Jessica St. Romain, MA
CONTACT
Melissa Harris, MA
CONTACT
Owen Carmichael, PhD
CONTACT
Robert L Newton, Jr., PhD
CONTACT
Alzheimer's disease is steadily increasing in prevalence, with a devastating public health impact. The prevalence of Alzheimer's Disease is higher in African Americans compared to white Americans, thereby constituting a health disparity. Interventions that prevent Alzheimer's disease or change the course of cognitive decline associated with Alzheimer's disease are needed. Most older adults do not achieve recommended levels of physical activity, and this includes African Americans. Regular physical activity has proven to be a safe and effective means to enhance cognitive function in older adults ranging from cognitively healthy to mildly cognitively impaired. Therefore, our study is focused on physical activity promotion, a potent approach to modifying multiple neurobiological pathways implicated in Alzheimer's Disease. We evaluate exercise benefits among elderly African Americans, who are understudied and in whom the natural course of neurodegeneration, exercise effects on neuroprotection and neurodegeneration, and resulting clinical phenotypes may differ. A large body of existing data suggests that exercise improves cardiovascular and cerebrovascular functioning, and thus has the potential to enhance perivascular clearance of amyloid and reduce chronic brain tissue ischemia, among other beneficial effects. At the same time, chronic exercise has been shown to decrease central levels of inflammatory markers and increase central levels of neurotrophic factors, which in turn promote protection against Alzheimer's Disease neurodegeneration pathways via a variety of mechanisms. While physical activity interventions have been shown to have positive effects on these factors and on resultant cognitive functioning in older adults, nearly all interventions have had a negligible representation of African Americans. Prior data suggests that African Americans enter their elderly years against a backdrop of different lifespan exposures to a variety of factors relevant to neuroprotection and neurodegeneration, including cardiovascular risk, exercise, diet, and education. In addition, prior data suggests that the key genetic risk factor for Alzheimer's Disease (APOE) may have differing consequences for Alzheimer's Disease risk among African Americans, and other genetic differences have the potential to influence the brain benefits of physical activity in this community. We will utilize a randomized clinical trial to addresses these questions. Participants will be randomized into a physical activity promotion intervention or a healthy aging information group for 52 weeks. All participants will be of normal cognitive function. We will assess cognitive function, brain structure and function, circulating hormones, objectively measured physical activity, cardiorespiratory fitness, and telomere length. Our study will take the first step toward understanding whether the hypothesized benefits of exercise for the brain carry over to elderly African Americans.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Promotion of physical activity to the current federal physical activity guidelines.
Seminars of health topics related to aging in African Americans with light stretching and low intensity activites
Time frame: Baseline, 24 weeks, 52 weeks
The Rey Auditory Verbal Learning Test (RAVLT) is a common neuropsychological tool used to evaluate episodic memory. The RAVLT involves providing participants with 15 unrelated words and asking them to recall the word list. There are 5 trials designed to determine short-term memory and then a 30 minute delay to assess long-term memory. The total words correct in both the short- and long-term trials are used as outcome measures.
Time frame: Baseline, 24 weeks, 52 weeks
The NIH Toolbox Executive Function subdomain consists of the Flanker Inhibitory Control and Attention Test and the Dimensional Change Card Sort Test. The Flanker test is a measure of one's ability to inhibit attention to irrelevant conditions. Participants must identify the direction of a central visual stimuli amongst flanking stimuli either congruent or incongruent with the central stimuli. There are 40 trials and scores range from 0 - 10. The Card Sort is a measure of the ability to shift attention based on rules. Participants must match a target visual stimuli to either a color or word stimuli and this matching shifts during the assessment.
Time frame: Baseline, 24 weeks, 52 weeks
The Mini-Mental Status Examination is 30-point questionnaire to assess cognitive impairment.
Time frame: Baseline, 24 weeks, 52 weeks
Fasting levels of glucose will be assessed using standard assays.
Time frame: Baseline, 24 weeks, 52 weeks
The Actigraph WGT3X+ accelerometer (ActiGraph LLC, Pensacola, FL) will be worn by the participant for a 7-day period. The device provides both the number of steps per day as well as time in sedentary, light, moderate, and vigorous activity in 1-minute epochs (for adults) using the default filter.
Time frame: Baseline, 24 weeks, 52 weeks
All participants will perform a standardized graded exercise testing protocol administered on a treadmill. Fitness will be measured in terms of mL oxygen/kg/min.
Time frame: Baseline, 24 weeks, 52 weeks
Physical function will be assessed using the NIH-TB Motor assessment, which assesses dexterity, balance, locomotion, grip strength, and strength.
Time frame: Baseline, 24 weeks, 52 weeks
DNA will be extracted from the blood draw and amplified using real-time quantitative polymerase chain reaction (qPCR) to determine average relative telomere length represented by the telomere repeat copy number to single gene copy number (T/S) ratio in triplicate as previously described
Time frame: Baseline, 24 weeks, 52 weeks
Weight will be measured using a standard stadiometer. Measurements will be taken to the nearest cm.
Time frame: Baseline, 24 weeks, 52 weeks
Volumes of the cranial vault, brain tissue, gray matter, white matter, and cerebrospinal fluid, which will be provided as the primary brain structural outcome measures of interest from MRI.
Time frame: Baseline, 24 weeks, 52 weeks
Pre-selected inhibitory control ROIs (ACC for the Stroop; DLPFC, thalamus, superior frontal, inferior frontal, fusiform, and middle frontal gyri; and ACC and middle frontal gyri for the ANT) are of primary interest.
Time frame: Baseline, 24 weeks, 52 weeks
Fasting levels of lipids will be assessed using standard assays.
Time frame: Baseline
APOE genotype will be assessed using standard assays.
Time frame: Continuously for 52 weeks
The Fitbit Charge 2 will be worn by participants in both groups.
Time frame: Blood pressure will be measured using the Omron, Model BP710 automatic blood pressure cuff.
Blood pressure will be measured using the Omron, Model BP710 automatic blood pressure cuff.
Time frame: Baseline, 24 weeks, 52 weeks
The Geriatric Depression Scale will be used to measure depressive symptoms.
Time frame: Baseline, 24 weeks, 52 weeks
Height will be assessed using a standard stadiometer.
Time frame: Baseline, 24 weeks, 52 weeks
Physical function will be assessed using the the Short Physical Performance Battery (SPPB), which is a brief performance battery based on timed short distance walk, repeated chair stands and balance test.
Contact information is provided by the study sponsor or research team.
Pennington Biomedical Research Center
Other
Acronym: RAATE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07154394
Alzheimer Disease, Amyloid Neuropathies
Essen, North Rhine-Westphalia, Germany
View Trial DetailsNCT03672266
ADHD, Alzheimer Disease
Piscataway, New Jersey, United States
View Trial DetailsNCT03846492
Aberrant Motor Behavior in Dementia, Alzheimer Disease
Toronto, Ontario, Canada
View Trial DetailsNCT03153371
Alzheimer Disease, Alzheimer Disease, Early Onset
Los Angeles, California, United States
View Trial Details